http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Bairong (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Ting-Ting Chen,Junfen Xu,Bairong Xia,Hui Wang,Yuanming Shen 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.1
Background: Epithelial ovarian cancer is the leading cause of death among gynecologicalmalignancies. Platinum resistance remains a dilemma and bottleneck in treatment, andsalvage chemotherapy has limited effectiveness. Recently, the role of secondar y cytoreductivesurger y (SCS) in patients with platinum-resistant recurrent ovarian cancer (ROC) has causedattention especially in patients with oligometastases. However, there is neither high-qualityevidence-based evidence nor standardized criteria for selecting SCS for patients withplatinum-resistant ROC until now. Methods: This multicenter, randomized, controlled clinical trial is to evaluate the valueof SCS and to clarif y reliable criteria of utilizing SCS in women with ROC, which is led byGynecologic Oncology Group, Women’s Hospital, Zhejiang University School of Medicine. Recruitment has started on Januar y 1st, 2023, and is scheduled to end in December 2026. One hundred and forty participants with platinum-resistant ROC who meet the “RSCScriteria” will be randomized assigned at a ratio of 1:1 to either the experimental arm or thestandard arm. Patients in the experimental arm will receive SCS followed by non-platinumsingle agent chemotherapy (paclitaxel, gemcitabine or liposomal adriamycin) for at least4 cycles while patients in the standard arm will be provided with only non-platinum singleagent chemotherapy. The primar y outcome is progression-free sur vival. The secondar youtcomes are overall sur vival, adverse events and health-related cancer-specific quality of life. Trial Registration: ClinicalTrials.gov Identifier: NCT05633199
-
Emerging 3D bioprinting applications in plastic surgery
Yang Pu,Ju Yikun,Hu Yue,Xie Xiaoyan,Fang Bairong,Lei Lanjie 한국생체재료학회 2023 생체재료학회지 Vol.27 No.00
Plastic surgery is a discipline that uses surgical methods or tissue transplantation to repair, reconstruct and beautify the defects and deformities of human tissues and organs. Three-dimensional (3D) bioprinting has gained widespread attention because it enables fine customization of the implants in the patient's surgical area preoperatively while avoiding some of the adverse reactions and complications of traditional surgical approaches. In this paper, we review the recent research advances in the application of 3D bioprinting in plastic surgery. We first introduce the printing process and basic principles of 3D bioprinting technology, revealing the advantages and disadvantages of different bioprinting technologies. Then, we describe the currently available bioprinting materials, and dissect the rationale for special dynamic 3D bioprinting (4D bioprinting) that is achieved by varying the combination strategy of bioprinting materials. Later, we focus on the viable clinical applications and effects of 3D bioprinting in plastic surgery. Finally, we summarize and discuss the challenges and prospects for the application of 3D bioprinting in plastic surgery. We believe that this review can contribute to further development of 3D bioprinting in plastic surgery and provide lessons for related research. Graphical Abstract
-
A Novel Accessory Molecule Trim59 Involved in Cytotoxicity of BCG-Activated Macrophages
Xiangfeng Zhao,Dongmei Yan,Qihui Liu,Baiqiu Du,Peng Li,Qu Cui,Xiao Han,Bairong Du,Xun Zhu 한국분자세포생물학회 2012 Molecules and cells Vol.34 No.3
BCG-activated macrophages (BAM) could kill the tumor cells through cell-cell contact. In this process membrane proteins play an important role. However, up to date, few membrane proteins were revealed. In this study, we se-lected a surface molecule named Trim59, which was spe-cifically expressed on BAM membrane (compared with the negative control). We cloned and prokaryoticly expressed the extracellular domain of Trim59, purified the recombinant protein and generated polyclonal antibodies. Immunohistochemistry showed that Trim59 abundantly expressed in spleen, stomach and ovary; intermediately expressed in brain, lung, kidney, muscle and intestine; but not in thymus, liver, heart, uterus. Using the antibodies to block Trim59 on BAM significantly reduced BAM cyto-toxicity against MCA207 cells. This demonstrated that Trim59 serves as an indispensable molecule in maintaining BAM activity. Overexpression of Trim59 in Raw264.7 cell line failed to lyse target MCA207 cells, which potentiated Trim59 per se could not enhance macrophage cytotoxicity; on another hand, overexpression of Trim59 enhance the pinocytosis and Phagocytosis activity of Raw-264.7, which imply Trim59 might mediate the cell-molecule interaction. Our results indicate Trim59 might be an essential accessory molecule in mediating BAM tumoricidal functions; and Trim59 is a phagocytosis-correlated molecule.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
